Dentist Los Angeles | Dentist Beverly Hills | General Dentist | Cosmetic Dentist | Dental Implant | Dental Office
 

www.zdentalgroup.com

 

This Smile Brought To You By Science-StrixNB(TM); Kane Biotech Introduces …

Posted by Z Dental Group - February 1st, 2013

Kane Biotech Inc. (TSX VENTURE:KNE), will launch a selling margin exam for StrixNB, a insubordinate new pet oral caring product, in Manitoba on Feb 1, 2013 in and with Pet Dental Health Month. Kane Biotech is a biotechnology association intent in a expansion and commercialization of products that forestall and mislay microbial biofilms. Manitoba pet owners will be a initial in Canada to have entrance to this easy-to-use messenger animal oral caring product that has a intensity to change a approach we caring for a pets’ teeth.

StrixNB is a new, stable and effective celebration H2O further scientifically formulated to assistance say and foster good dental and oral hygiene in pets. It is singular since it works opposite germ compared with dental illness by altering a mouth’s environment. It breaks by dental biofilm – a rarely structured, matrix-embedded microbial race – creation germ permitted for expulsion by a microbial agent.

When we take caring of your pet’s dental health, we assistance keep your pet – and we – worry-free. Dental diseases means annoy and can lead to discontinued ardour and weight loss. Worse still: some dental diseases, such as periodontal disease, can emanate germ means to transport into your pet’s bloodstream, inspiring a lungs, heart, kidneys, liver and shaken system.

StrixNB is done regulating a singular plan of food class mixture and has perceived a presentation series NN.1Q11 from a Interim Notification Program of Health Canada for Low Risk Veterinary Health Products. It is stable for bland expenditure and works for all breeds and sizes of dogs.

About Kane Biotech Inc.

Kane Biotech is a biotechnology association intent in a expansion and commercialization of products to forestall and mislay biofilms. Biofilms are a vital means of a series of critical medical problems including ongoing infections and medical device compared infections. They rise on surfaces such as catheters, prosthetic implants, teeth, lungs and a urogenital tract. Biofilms are pervasive, dear to understanding with, and are concerned in approximately 80 per cent of all tellurian bacterial infections. The recovering of ongoing wounds alone costs a United States health caring complement $20 Billion per year.

Kane Biotech uses obvious stable technologies formed on molecular mechanisms of biofilm formation/dispersal and methods for anticipating compounds that stop or interrupt biofilms. The Company has justification that these technologies have intensity to significantly urge a ability to forestall and/or destroy biofilms in several medical and industrial applications.

Caution Regarding Forward-Looking Information

Certain statements contained in this press recover consecrate forward-looking information within a definition of germane Canadian provincial bonds legislation (collectively, “forward-looking statements”). These forward-looking statements describe to, among other things, a objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, including, but limitation, a expected destiny handling results, and can, in some cases, be identified by a use of difference such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “will,” “may” and other identical expressions. In addition, any statements that impute to expectations, projections or other characterizations of destiny events or resources are forward-looking statements.

These statements simulate management’s stream beliefs and are formed on information now accessible to management. Certain element factors or assumptions are practical in creation forward-looking statements, and tangible formula might differ materially from those voiced or pragmatic in such statements. Important factors that could means tangible formula to differ materially from these expectations include, among other things: Kane’s early theatre of development, miss of product revenues and story of handling losses, uncertainties compared to clinical trials and product development, fast technological change, uncertainties compared to forecasts, competition, intensity product liability, additional financing mandate and entrance to capital, unproven markets, supply of tender materials, income taxation matters, government of growth, partnerships for expansion and commercialization of technology, effects of insurers’ eagerness to compensate for products, complement failures, coherence on pivotal personnel, unfamiliar banking risk, risks compared to regulatory matters and risks compared to egghead skill and other risks minute from time to time in Kane’s filings with Canadian bonds regulatory authorities, as good as Kane’s ability to expect and conduct a risks compared with a foregoing. Kane cautions that a foregoing list of critical factors that might impact destiny formula is not exhaustive. When relying on Kane’s forward-looking statements to make decisions with honour to Kane, investors and others should delicately cruise a foregoing factors and other uncertainties and intensity events.

These risks and uncertainties should be deliberate delicately and impending investors should not place undue faith on a forward-looking statements. Although a forward-looking statements contained in this press recover are formed on what government believes to be reasonable assumptions, Kane can't yield declaration that tangible formula will be unchanging with these forward-looking statements. Kane undertakes no requirement to refurbish or correct any forward-looking statement.

Neither a TSX Venture Exchange nor a Regulation Services Provider (as that tenure is tangible in a policies of a TSX Venture Exchange) accepts shortcoming for a endowment or correctness of this release.

SOURCE: Kane Biotech Inc.

Copyright 2013 Marketwire, Inc.

All Rights Reserved

Shared Post

    Tags: ,

    Leave a Reply

    You must be logged in to post a comment.

    Blog Home